Medical Device Market Access: A VAC-Proof Strategy for Your First Launch

2026-08-18 · Caduvo Team

Learn how to build a medical device market access strategy that moves your technology past the hospital value analysis committee—coding, evidence, and realistic go-to-market sequencing.

A surgeon wants your device. The department chair signs off. Then the value analysis committee (VAC) kills it in a 45-minute meeting. Medical device market access is not a clinical trial problem; it is an evidence, coding, and workflow problem. This post explains how to build a strategy that gets through the VAC and into the supply chain.

What Medical Device Market Access Actually Means for Device Makers

Market access is the set of activities that moves a cleared device from regulatory approval to paid usage in a health system. It includes FDA clearance, CPT/HCPCS coding, payer coverage, hospital contracting, and VAC approval. Miss any one, and revenue stalls. For medtech market access, the hospital is often the real gatekeeper, not Medicare. Private payers may follow Medicare's lead, but hospitals make the final buy decision. A device can be FDA-cleared and have a code and still get rejected because the VAC doesn't see a financial or clinical reason to switch.

If you're unsure about coding, start with HCPCS vs CPT codes. Without a payment code, a hospital cannot bill for your device separately in many outpatient and physician-office settings.

How Hospital Value Analysis Committees Evaluate New Products

A value analysis committee is typically a cross-functional group: supply chain, nursing, surgeons, finance, infection control, sometimes pharmacy. They meet monthly or biweekly to review new product requests. The process often starts with a standardized request form that asks: What problem does this solve? What does it replace? What's the cost per procedure or per patient day? What clinical evidence supports it? What are implementation requirements?

VACs use decision rules. Many committees have a threshold for new technology: if it costs more than the incumbent, the sponsor must show a hard clinical outcome improvement—lower length of stay, fewer readmissions, fewer revisions—not just convenience. They also look for a physician champion, but a champion without data gets nowhere. Expect them to ask for a pilot or limited trial before system-wide adoption.

Typical VAC request packages include:

The Clinical and Economic Evidence Buyers Actually Ask For

The evidence package is not the FDA 510(k) summary. VACs want outcomes data in their own patient population. Start with published studies from peer-reviewed journals. If you only have bench or animal data, expect rejection. A single-center retrospective study with 50 patients can be enough for a pilot, but not for a system-wide rollout.

Economic evidence matters just as much. Build a simple budget impact model: device cost minus offsetting savings (e.g., fewer reoperations, shorter procedure time, less waste). If your device costs $1,200 more per case but reduces length of stay by 0.8 days, show that dollar value. Supply chain teams think in cost per case, not cost per device.

VACs also compare against alternatives. If there is a GPO contract for a competing product, you need to explain why the hospital should break that contract or add an exception. Sometimes the answer is no, and the best strategy is to wait for the next contract cycle.

Evidence categories that matter, in order of weight:

  1. Clinical evidence: at least one peer-reviewed study with relevant endpoints (length of stay, complications, revisions).
  2. Economic evidence: budget impact model, cost-effectiveness analysis if available.
  3. Operational evidence: setup time, sterile processing requirements, training burden.
  4. Real-world evidence: early adopter data or a proposed pilot within the hospital.

A Realistic Go-to-Market Sequencing for a First Device

If you are launching your first device, do not start with the VAC. Sequence matters. Follow these steps:

  1. FDA clearance or approval: 510(k) or De Novo. For breakthrough devices, there may be transitional coverage options, but not guaranteed. See Breakthrough Device Designation for what it actually gets you.
  2. Coding: Determine if an existing CPT or HCPCS code applies, or if you need a new one. Without a code, hospitals cannot bill for your device separately in many cases.
  3. Payer coverage: Check Medicare LCDs and NCDs and private payer policies. If there is no coverage, hospitals may still buy, but it is harder. Use the Medicare coverage database.
  4. Hospital contracting: Get on the hospital's approved product list, often through a GPO or direct contract.
  5. VAC submission: Prepare the request form with evidence, pricing, and a physician champion. Expect one to three months for review, sometimes longer.
  6. Pilot or limited release: Negotiate a specific department or a small patient cohort to collect real-world data. Use that data to expand.

Common mistake: trying to get VAC approval before coding and coverage are settled. If the committee asks "How will we bill for this?" and you don't have an answer, you lose.

Actionable Takeaways

Related reading